Anavex Life Sciences Corp (AVXL)

[Investor2014]

With what we now know, or rather what we still do not know, about Anavex and its clinical trial data in general, I am not sure the risk has been reduced compared with the period before the Phase 2a open-label AD trial.

What we do know, cabal or no cabal, is that the CHMP rejected the results as presented by Anavex.

Adding an in-trial generated hypothesis, such as ABCLEAR 2 and 3, does not equal risk reduction.

What I am sure of is that this statement will get Hosai busy with ChatGPT trying to prove me wrong.